# XLO (Xilio Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Xilio Therapeutics, Inc. reported $55.01M in revenue and a net loss of $11.49M for the trailing twelve months ended September 30, 2026 (down 47.6% year over year), with a -74.9% operating margin.

- Canonical: https://convexityos.com/fundamentals/XLO
- Markdown: https://convexityos.com/fundamentals/XLO.md
- SEC CIK: 0001840233
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:52 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001840233&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $55.01M | -47.6% YoY |
| Operating Income | TTM | -$41.19M | -74.9% margin |
| Net Income | TTM | -$11.49M | -20.9% net margin |
| Diluted EPS | TTM | -$4.19 | Split-adjusted |
| Free Cash Flow | TTM | -$57.62M | -104.8% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $122.2M | Total debt: $5.96M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $43.77M | $6.34M | -- | -- | -- | -- |
| Research & Development | $56.04M | $41.21M | $52.14M | $59.20M | $51.19M | $43.91M |
| Total Operating Expenses | $85.75M | $66.93M | $79.13M | $89.15M | $75.04M | $54.56M |
| **Operating Income** | -$41.98M | -$60.58M | -$79.13M | -$89.15M | -$75.04M | -$54.56M |
| **EBITDA** | -$40.44M | -$58.94M | -$77.23M | -$87.30M | -$73.55M | -$53.50M |
| Income Before Tax | -$35.04M | -$58.24M | -- | -- | -- | -- |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$35.04M | -$58.24M | -$76.40M | -$88.22M | -$75.80M | -$55.22M |
| Basic EPS | -$4.19 | -$15.24 | -$38.94 | -$45.10 | -$189.36 | -$1,476.47 |
| **Diluted EPS** | -$4.19 | -$15.24 | -$38.94 | -$45.10 | -$189.36 | -$1,476.47 |
| Basic Shares Outstanding | 8.4M | 3.8M | 2.0M | 2.0M | 400.3K | 37.4K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $9.98M | $18.69M | $12.65M | $13.69M | $19.07M | $8.08M | $2.93M | -- |
| Research & Development | $14.80M | $14.56M | $19.83M | $18.12M | $14.32M | $15.33M | $8.27M | $8.84M |
| Total Operating Expenses | $21.73M | $22.18M | $26.76M | $25.52M | $21.00M | $22.45M | $16.78M | $15.35M |
| **Operating Income** | -$11.75M | -$3.49M | -$14.11M | -$11.84M | -$1.93M | -$14.37M | -$13.85M | -$13.63M |
| **EBITDA** | -$11.43M | -$3.16M | -$13.77M | -$11.51M | -$1.59M | -$13.98M | -$13.35M | -$13.25M |
| **Net Income** | -$5.95M | -$6.37M | -$9.53M | $10.36M | -$16.29M | -$15.84M | -$13.27M | -$13.09M |
| Basic EPS | -$0.30 | -$0.33 | -$0.58 | -- | -$1.58 | -$2.30 | -$2.49 | -- |
| **Diluted EPS** | -$0.30 | -$0.33 | -$0.58 | -- | -$1.58 | -$2.30 | -$2.49 | -- |
| Basic Shares Outstanding | 19.7M | 19.4M | 16.3M | -- | 10.3M | 6.9M | 5.3M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $137.5M | $55.29M | $44.70M | $120.4M | $198.1M | $19.24M |
| **Cash & Short-Term Investments** | $137.5M | $55.29M | $44.70M | $120.4M | $198.1M | $19.24M |
| Other Current Assets | -- | -- | -- | -- | -- | $44K |
| **Total Current Assets** | $145.0M | $60.23M | $48.13M | $124.5M | $202.5M | $20.59M |
| Property, Plant & Equipment, Net | $3.89M | $4.47M | $5.94M | $7.25M | $7.62M | $7.37M |
| Other Non-Current Assets | -- | -- | $145K | $267K | $393K | $500K |
| **Total Non-Current Assets** | $9.66M | $10.84M | $12.80M | $14.67M | $15.54M | $15.73M |
| **Total Assets** | $154.7M | $71.08M | $60.93M | $139.2M | $218.1M | $36.32M |
| Accounts Payable | $3.17M | $2.57M | $1.05M | $3.12M | $3.14M | $5.44M |
| Deferred Revenue (Current) | $40.02M | $13.52M | -- | -- | -- | -- |
| Other Current Liabilities | -- | -- | $48K | $82K | $82K | $82K |
| **Total Current Liabilities** | $56.27M | $27.26M | $15.96M | $21.12M | $12.78M | $22.16M |
| Deferred Revenue (Non-Current) | $20.64M | $19.26M | -- | -- | -- | -- |
| Other Non-Current Liabilities | -- | -- | -- | $45K | $118K | $1.13M |
| **Total Non-Current Liabilities** | $63.14M | $26.22M | $8.14M | $12.40M | $19.85M | $19.45M |
| **Total Liabilities** | $119.4M | $53.48M | $24.10M | $33.52M | $32.63M | $41.60M |
| **Total Debt (incl. Leases)** | $6.95M | $8.14M | $9.24M | $10.23M | $11.11M | $11.74M |
| Common Stock | $0 | $5.0K | $3.0K | $3.0K | $3.0K | -- |
| Retained Earnings | -$418.8M | -$383.8M | -$325.5M | -$249.1M | -$160.9M | -$85.09M |
| **Total Stockholders' Equity** | $35.27M | $17.60M | $36.83M | $105.6M | $185.4M | -$83.29M |
| Total Equity | $35.27M | $17.60M | $36.83M | $105.6M | $185.4M | -$83.29M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $122.2M | $136.0M | $150.3M | $137.5M | $103.8M | $121.6M | $89.07M | $55.29M |
| **Cash & Short-Term Investments** | $122.2M | $136.0M | $150.3M | $137.5M | $103.8M | $121.6M | $89.07M | $55.29M |
| **Total Current Assets** | $126.5M | $145.5M | $154.2M | $145.0M | $124.1M | $123.7M | $93.20M | $60.23M |
| Property, Plant & Equipment, Net | $3.09M | $3.36M | $3.68M | $3.89M | $3.68M | $4.02M | $4.29M | $4.47M |
| **Total Non-Current Assets** | $8.33M | $8.79M | $9.28M | $9.66M | $9.61M | $10.10M | $10.52M | $10.84M |
| **Total Assets** | $134.8M | $154.3M | $163.5M | $154.7M | $133.7M | $133.8M | $103.7M | $71.08M |
| Accounts Payable | $753K | $2.31M | $1.06M | $3.17M | $2.30M | $4.10M | $2.27M | $2.57M |
| Deferred Revenue (Current) | $15.41M | $22.60M | $31.54M | $40.02M | $43.85M | $42.28M | $40.25M | $13.52M |
| **Total Current Liabilities** | $26.80M | $34.20M | $42.96M | $56.27M | $56.40M | $53.26M | $47.64M | $27.26M |
| Deferred Revenue (Non-Current) | $9.93M | $12.71M | $16.47M | $20.64M | $25.50M | $28.63M | $38.74M | $19.26M |
| **Total Non-Current Liabilities** | $39.80M | $47.79M | $47.98M | $63.14M | $85.39M | $73.48M | $45.38M | $26.22M |
| **Total Liabilities** | $66.60M | $81.99M | $90.94M | $119.4M | $141.8M | $126.7M | $93.02M | $53.48M |
| **Total Debt (incl. Leases)** | $5.96M | $6.30M | $6.64M | $6.95M | $7.26M | $7.57M | $7.86M | $8.14M |
| Common Stock | $1.0K | $1.0K | $1.0K | $0 | $5.0K | $5.0K | $5.0K | $5.0K |
| Retained Earnings | -$440.6M | -$434.7M | -$428.3M | -$418.8M | -$429.1M | -$412.9M | -$397.0M | -$383.8M |
| **Total Stockholders' Equity** | $68.23M | $72.26M | $72.55M | $35.27M | -$8.10M | $7.07M | $10.70M | $17.60M |
| Total Equity | $68.23M | $72.26M | $72.55M | $35.27M | -$8.10M | $7.07M | $10.70M | $17.60M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$35.04M | -$58.24M | -$76.40M | -$88.22M | -$75.80M | -$55.22M |
| Depreciation & Amortization | $1.54M | $1.64M | $1.90M | $1.85M | $1.50M | $1.06M |
| Stock-Based Compensation | $6.94M | $6.43M | $7.38M | $8.42M | $4.96M | $1.30M |
| Change in Receivables | -$5.00M | -- | -- | -- | -- | -- |
| Change in Payables | $152K | $1.53M | -$2.06M | $485K | -$2.82M | $2.93M |
| **Operating Cash Flow** | -$4.99M | -$18.38M | -$68.62M | -$75.72M | -$80.75M | -$36.09M |
| Capital Expenditure | -$518K | -$36K | -$486K | -$1.87M | -$1.10M | -$2.19M |
| **Free Cash Flow** | -$5.51M | -$18.41M | -$69.11M | -$77.59M | -$81.85M | -$38.28M |
| **Investing Cash Flow** | -$518K | -$36K | -$486K | -$1.87M | -$1.10M | -$2.19M |
| Common Stock Issued | -- | -- | -- | -- | $116.4M | -- |
| **Financing Cash Flow** | $87.78M | $29.20M | -$6.55M | -$69K | $260.7M | $10.03M |
| **Net Change in Cash** | $82.27M | $10.78M | -$75.66M | -$77.66M | $178.8M | -$28.25M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$5.95M | -$6.37M | -$9.53M | $10.36M | -$16.29M | -$15.84M | -$13.27M | -$13.09M |
| Depreciation & Amortization | $321K | $331K | $344K | $323K | $340K | $381K | $497K | $376K |
| Stock-Based Compensation | $1.92M | $1.60M | $2.21M | $2.93M | $1.12M | $1.35M | $1.53M | $1.52M |
| Change in Receivables | $6.00M | -$6.00M | $5.00M | $12.50M | -- | -- | $0 | -- |
| Change in Payables | -$1.55M | $1.26M | -$1.68M | $428K | -$1.80M | $2.11M | -$590K | $1.60M |
| **Operating Cash Flow** | -$13.79M | -$18.76M | -$22.34M | -$2.00M | -$17.50M | -$14.48M | $28.98M | -$14.16M |
| Capital Expenditure | -$58K | -$19K | -$556K | -$95K | $0 | -$401K | -$22K | -- |
| **Free Cash Flow** | -$13.85M | -$18.78M | -$22.90M | -$2.09M | -$17.50M | -$14.88M | $28.96M | -- |
| **Investing Cash Flow** | -$58K | -$19K | -$556K | -$95K | $0 | -$401K | -$22K | -- |
| **Financing Cash Flow** | $0 | $4.49M | $35.71M | $35.87M | -$285K | $47.36M | $4.83M | $8.20M |
| **Net Change in Cash** | -$13.85M | -$14.29M | $12.81M | $33.77M | -$17.78M | $32.48M | $33.79M | -$5.96M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -95.9% | -954.9% | -- | -- | -- | -- |
| **Net Profit Margin** | -80.1% | -918.0% | -- | -- | -- | -- |
| Return on Equity (ROE) | -99.3% | -331.0% | -207.5% | -83.5% | -40.9% | -- |
| Return on Assets (ROA) | -22.6% | -81.9% | -125.4% | -63.4% | -34.8% | -152.0% |
| Current Ratio | 2.58x | 2.21x | 3.02x | 5.89x | 15.85x | 0.93x |
| Quick Ratio | 2.44x | 2.03x | 2.80x | 5.70x | 15.50x | 0.87x |
| Debt to Equity | 0.20x | 0.46x | 0.25x | 0.10x | 0.06x | -- |
| **Revenue Growth (YoY)** | +589.9% | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -74.9% | -48.9% | -79.0% | -95.9% | -- | -- | -- | -- |
| **Net Profit Margin** | -20.9% | -34.1% | -58.5% | -80.1% | -- | -- | -- | -- |
| Return on Equity (ROE) | -16.8% | -30.2% | -43.1% | -99.3% | -- | -795.3% | -507.5% | -331.0% |
| Return on Assets (ROA) | -8.5% | -14.2% | -19.1% | -22.6% | -43.7% | -42.0% | -52.4% | -81.9% |
| Current Ratio | 4.72x | 4.25x | 3.59x | 2.58x | 2.20x | 2.32x | 1.96x | 2.21x |
| Quick Ratio | 4.56x | 3.98x | 3.50x | 2.44x | 1.84x | 2.28x | 1.87x | 2.03x |
| Debt to Equity | 0.09x | 0.09x | 0.09x | 0.20x | -- | 1.07x | 0.73x | 0.46x |
| **Revenue Growth (YoY)** | -47.6% | +131.2% | +331.7% | -- | +742.5% | +243.0% | -- | -- |
| Operating Cash Flow Growth (YoY) | -- | -- | -177.1% | -- | -- | -172.6% | -- | -- |
| Free Cash Flow Growth (YoY) | -- | -- | -179.1% | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
